Industry
Biotechnology
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Loading...
Open
0.89
Mkt cap
14M
Volume
89K
High
0.91
P/E Ratio
-0.78
52-wk high
5.28
Low
0.82
Div yield
N/A
52-wk low
0.72
Portfolio Pulse from
November 28, 2024 | 4:15 pm
Portfolio Pulse from
November 18, 2024 | 12:15 pm
Portfolio Pulse from
November 13, 2024 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 11:04 am
Portfolio Pulse from Benzinga Newsdesk
September 24, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 11:00 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.